Sponsored by
Preclinical studies recently published in Neuro-Oncology showed that an investigational circadian-targeting drug, SHP1705, impaired glioblastoma (GBM) stem cell survival, enhanced response to radiation, and slowed tumor growth in animal models. A phase I trial in healthy volunteers confirmed safety, and there are now plans for an upcoming phase II trial in GBM patients. Researchers are also exploring combinations with other circadian-targeting drugs, which may further improve the potential impact.